Understand low testosterone cutoffs, repeat testing, symptoms and the roles of SHBG and free testosterone in a clinician-led diagnosis.
What counts as low testosterone? For late-onset hypogonadism, it means compatible signs and symptoms plus consistently low testosterone, not just one result below a laboratory cutoff.
This article is for informational purposes and is not medical advice. Personal testing and treatment decisions belong with a qualified clinician.
The European Association of Urology (EAU) guidelines identify total testosterone of 12 nmol/L (3.5 ng/mL) as a reliable threshold for late-onset hypogonadism. However, the guideline applies that threshold alongside symptoms and clinical assessment. It does not make the number a stand-alone diagnosis.
A 2026 article in Clinical Chemistry reports that the Endocrine Society’s 2018 guideline used a morning total-testosterone threshold below 264 ng/dL (9.2 nmol/L) in relevant clinical scenarios. These published thresholds differ. Neither should be presented as a universally agreed boundary that settles every case.
The practical question is not simply whether a result falls below a number found online. It is which guideline applies and how the measurement fits the clinical picture. That distinction matters when reading a report that flags testosterone as low.
A clinician can explain the threshold being used and why it is relevant to the assessment. Understanding the difference between a laboratory range and a diagnosis helps keep the printed result in perspective.
The EAU recommends investigating late-onset hypogonadism in symptomatic men rather than systematically screening men without symptoms. The blood test is intended to help confirm a suspected clinical problem.
The guideline distinguishes between symptoms with different levels of specificity:
“More specific” does not mean definitive. The EAU cautions that symptoms are not exclusive to hypogonadism. Their meaning depends on the broader clinical and biochemical assessment.
This also explains why an online symptom score cannot establish the diagnosis. The guideline says self-reported questionnaires and structured interviews have poor specificity for systematic screening.
For a clinical conversation, describing the actual concern is more useful than assigning it a hormone label. Reduced sexual interest and persistent low energy are different observations. The clinician needs to understand those observations before interpreting the blood result.
Our discussion of putting sexual changes in context addresses this distinction in more detail.
The EAU recommends morning fasting total-testosterone testing with a reliable laboratory assay. When the result is below its threshold, the guideline calls for measurements on at least two separate occasions before testosterone therapy.
The purpose is to establish whether low testosterone is consistent. A single measurement records the result from one sampling occasion. It does not establish that the same finding persists under appropriate testing conditions.
Confirmation is therefore about more than collecting another laboratory report. The conditions surrounding the measurements matter too. A clinician needs to know whether the results provide a suitable basis for comparison.
Useful questions for that discussion include whether the original sample was taken under the recommended conditions and how confirmation should be arranged. These questions support clinical interpretation rather than create a self-diagnosis checklist.
The distinction between an initial finding and a confirmed pattern is central to making sense of a first low result. Repetition addresses consistency; the later stages of assessment address what the finding means and what may explain it.
The EAU recommends fasting morning sampling between 07:00 and 10:00. Its guideline reports that non-fasting measurement can underestimate total testosterone by more than 30%. That is a reason to consider sampling conditions, not a correction factor to apply to an individual result.
The same guideline recognizes that the usual morning window may not suit night-shift workers. For those workers, it advises fasting sampling after adequate sleep. The relevant discussion therefore includes the person’s work and sleep schedule rather than the clock alone.
Acute illness is another important context. The EAU notes that acute disease can be associated with functional hypogonadism and advises avoiding testosterone measurement in that setting.
A clinician reviewing a low result needs to know whether the sample followed a meal or was collected during illness. Night-shift work and sleep disruption also belong in that conversation. These details help establish whether the measurement was obtained in an appropriate setting.
They should not be used to dismiss ongoing symptoms. Their role is to improve the interpretation of the laboratory evidence.
The EAU describes LC-MS/MS as the most accurate method for evaluating sex steroids. It also states that standardized automated immunoassays correlate well with LC-MS/MS for total testosterone.
The distinction matters because “immunoassay” is not a reason to reject every total-testosterone result. The guideline supports reliable measurement rather than a blanket claim that only one method can contribute to diagnosis.
Free-testosterone testing requires a different interpretation. According to the EAU, available immunoassays do not accurately estimate free testosterone. It advises against direct free-testosterone evaluation using those methods and identifies equilibrium dialysis as the most accurate method.
The guideline also describes calculated free testosterone as an alternative. That calculation uses total testosterone, SHBG and albumin.
When a report includes free testosterone, a useful question is whether the value was measured or calculated. If it was measured directly, the method matters. This is more informative than assuming that any result labeled “free testosterone” has the same meaning or reliability.
The broader principle is to match the measurement method to the clinical question being asked.
Total testosterone is an important starting point, but the EAU recommends considering SHBG and calculated free testosterone when indicated. This is particularly relevant in conditions associated with altered SHBG. The guideline lists obesity and ageing among those factors.
That recommendation gives related biomarkers a defined role. They provide additional context in selected situations rather than replacing total testosterone in every assessment.
When total testosterone is borderline or SHBG may be altered, a clinician may consider whether free-testosterone assessment would clarify the picture. The choice should follow the clinical context and use a suitable measurement or calculation method.
A helpful way to organize the discussion is to separate three questions:
This keeps the purpose of each test visible. The aim is not to collect the largest possible hormone panel. It is to establish which measurements answer a relevant question in that assessment.
For more background, see our explanation of how related hormone measurements fit together. The key is context rather than treating every biomarker as a separate verdict.
Once consistently low testosterone has been established, the assessment turns toward possible causes and contributing factors. The EAU recommends reviewing diseases, drugs and substances that may affect testosterone production or action.
It also recommends measuring LH and FSH to help distinguish types of hypogonadism. These measurements address a different question from total testosterone: they help characterize the hormonal problem rather than simply repeat the initial finding.
A physician or endocrinologist brings these strands together. Symptoms explain the clinical concern. Sampling conditions and assay quality establish how to interpret the measurements. Relevant health conditions and additional biomarkers help place the findings in context.
Useful topics for an appointment include:
This is the point at which the conversation moves beyond whether a report is marked low. A low result is a reason for assessment, not an automatic indication for TRT. Any treatment decision requires an individual clinical discussion.
The EAU recommends rigorous measurement methods and CDC-certified total-testosterone thresholds through the Hormone Standardization Program. This places laboratory comparability alongside the other parts of diagnostic assessment.
For now, the practical approach is to understand which question each piece of evidence answers. A threshold helps interpret a measurement. Symptoms establish the clinical concern. Related biomarkers and health history help explain the wider picture.
Could better laboratory standardization and more precise use of SHBG help future research bring greater agreement to how low testosterone is defined?
Decisions about hormone testing sit with a man’s clinician; Testostra’s educational role is to make the report’s terms easier to follow. Its reporting on total testosterone, free testosterone and SHBG addresses confusion about related biomarkers so men can approach clinical conversations with a clearer understanding of the terms.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra